Factors impacting the combination of topical corticosteroid therapies for psoriasis: Perspectives from the international psoriasis council

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1130-1139

  Van De Kerkhof, P C M ^a   Kragballe, K ^b   Segaert, S ^c   Lebwohl, M ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMMONIUM LACTATE; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DESOXIMETASONE; DEXAMETHASONE 17 VALERATE; DIFLUCORTOLONE; HYDROCORTISONE; HYDROCORTISONE VALERATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PLACEBO; PROPYLENE GLYCOL; RETINOIC ACID; RETINOID; SALICYLIC ACID; TACALCITOL; TACROLIMUS; TAZAROTENE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; ONYCHOLYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SCALP PSORIASIS; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PSORIASIS;

EID: 80052967459     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04113.x     Document Type: Review

References (104)

1. National Psoriasis Foundation. About psoriasis; statistics. [WWW document. URL http://www.psoriasis.org/netcommunity/learn-statistics (last accessed: 5 May 2011).
2. Bikowski J, Pillai R, Shroot B,. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006; 5: 125-130.
3. el Tayar N, Tsai RS, Testa B, et al. Percutaneous penetration of drugs: a quantitative structure-permeability relationship study. J Pharm Sci 1991; 80: 744-749.
4. Cornell RC, Stoughton RB,. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121: 63-67.
5. Horn EJ, Domm S, Katz HI, et al. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol 2010; 24: 119-124.
6. World Health Organization. WHO Model Prescribing Information: Drugs Used in Skin Diseases. World Health Organization, Geneva, 1997.
7. Mason J, Mason AR, Cork MJ,. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-364.
8. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009; 41: 211-215.
9. Goon AT, Yosipovitch G, Chan YH, et al. Barrier repair in chronic plaque-type psoriasis. Skin Res Technol 2004; 10: 10-13.
10. Bos JD, Meinardi MM,. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9: 165-169.
11. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-1102.
12. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
13. Carroll CL, Clarke J, Camacho F, et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141: 43-46.
14. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141: 103-107.
15. Nagao K, Ishiko A, Yokoyama T, et al. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139: 1219.
16. Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006; 13: 175-187.
17. Ahmad N, Mukhtar H,. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol 2004; 123: 417-425.
18. Huttunen KM, Mahonen N, Raunio H, et al. Cytochrome P450-activated prodrugs: targeted drug delivery. Curr Med Chem 2008; 15: 2346-2365.
19. Smith G, Dawe RS, Clark C, et al. Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 2003; 121: 390-398.
20. Smith G, Ibbotson SH, Comrie MM, et al. Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol 2006; 155: 275-281.
21. Roeder A, Schaller M, Schafer-Korting M, et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 2005; 18: 3-11.
22. Mirshahpanah P, Docke WD, Merbold U, et al. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007; 16: 753-761.
23. Warino L, Balkrishnan R, Feldman SR,. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol 2006; 5: 527-532.
24. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-463.
25. Feldman SR, Yentzer BA,. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol 2009; 10: 397-406.
26. Wiren K, Frithiof H, Sjoqvist C, et al. Enhancement of bioavailability by lowering of fat content in topical formulations. Br J Dermatol 2009; 160: 552-556.
27. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.
28. Valencia IC, Kerdel FA,. Topical glucocorticoids. In, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine, 7th edn. Vol. 2. McGraw Hill, New York, 2008: 2102-2106.
29. Caron D, Queille-Roussel C, Shah VP, et al. Correlation between the drug penetration and the blanching effect of topically applied hydrocortisone creams in human beings. J Am Acad Dermatol 1990; 23: 458-462.
30. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-632.
31. Lombardi Borgia S, Schlupp P, Mehnert W, et al. In vitro skin absorption and drug release-a comparison of six commercial prednicarbate preparations for topical use. Eur J Pharm Biopharm 2008; 68: 380-389.
32. Leer JA Jr,. Efficacy of a betamethasone dipropionate topical glycol preparation in the management of severe psoriasis. Clin Ther 1980; 3: 156-167.
33. Faergemann J, Wahlstrand B, Hedner T, et al. Pentane-1,5-diol as a percutaneous absorption enhancer. Arch Dermatol Res 2005; 297: 261-265.
34. Anigbogu AN, Williams AC, Barry BW,. Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment. J Pharm Pharmacol 1996; 48: 357-366.
35. Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 120-124.
36. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
37. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
38. Kragballe K,. Management of difficult to treat locations of psoriasis. In:, Yawalkar N, ed. Management of Psoriasis, Current Problems in Dermatology. Vol. 38. Karger, Basel, Switzerland, 2009: 160-171.
39. Wozel G,. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008; 26: 448-459.
40. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269-274.
41. Griffiths CE, Finlay AY, Fleming CJ, et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17: 90-95.
42. Sanchez Regana M, Martin Ezquerra G, Umbert Millet P, et al. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005; 19: 573-577.
43. Farley E, Masrour S, McKey J, et al. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009; 60: 1024-1031.
44. Schwarb FP, Imanidis G, Smith EW, et al. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 1999; 16: 909-915.
45. Pellanda C, Ottiker E, Strub C, et al. Topical bioavailability of triamcinolone acetonide: effect of dose and application frequency. Arch Dermatol Res 2006; 298: 221-230.
46. Katz HI, Hien NT, Prawer SE, et al. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123: 1308-1311.
47. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39: 447-450.
48. Wilhelm KP, Surber C, Maibach HI,. Effect of sodium lauryl sulfate-induced skin irritation on in vitro percutaneous absorption of four drugs. J Invest Dermatol 1991; 96: 963-967.
49. Beutner K, Chakrabarty A, Lemke S, et al. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006; 5: 357-360.
50. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006; 78: 348-354.
51. Stein L,. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S39-S49.
52. Reid DC, Kimball AB,. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005; 6: 1735-1740.
53. Gottlieb AB, Ford RO, Spellman MC,. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185-192.
54. Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303-307.
55. Andreassi L, Giannetti A, Milani M,. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: 134-138.
56. Poulin Y, Papp K, Bissonnette R, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010; 21: 185-192.
57. Bovenschen H, Van de Kerkhof P,. Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice. J Eur Acad Dermatol Venereol 2010; 24: 439-444.
58. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-411.
59. Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998; 38: 1010-1011.
60. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
61. Lavker RM, Kaidbey K, Leyden JJ,. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. J Am Acad Dermatol 1992; 26: 535-544.
62. Cheng R, Krazmien R, Czopp M, et al. Compatibility of ammonium lactate 12% with halobetasol proprionate 0.05% and hydrocortisone valerate 0.2%. Psoriasis Forum 2008; 14: 5-7.
63. Huber C, Christophers E,. "Keratolytic" effect of salicylic acid. Arch Dermatol Res 1977; 257: 293-297.
64. Lin AN, Nakatsui T,. Salicylic acid revisited. Int J Dermatol 1998; 37: 335-342.
65. Lebwohl M,. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999; 38: 16-24.
66. Lebwohl M, Gelfand JM, Tan MH,. Clinically significant therapeutic interactions for the practicing dermatologist. Adv Dermatol 1999; 14: 1-26.
67. Polano MK, Ponec M,. Dependence of corticosteroid penetration on the vehicle. Arch Dermatol 1976; 112: 675-680.
68. Krochmal L, Wang JC, Patel B, et al. Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 1989; 21: 979-984.
69. Guenther LC,. Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol 2004; 5: 71-77.
70. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20: 283-291.
71. Gisslen H, Nordin P,. A comparative study of two potent corticosteroid preparations in the treatment of psoriasis. Pharmatherapeutica 1979; 2: 173-176.
72. Crosti C, Finzi AF, Mian E, et al. Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid. Int J Dermatol 1997; 36: 537-539.
73. Scarpa C,. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Derm Venereol Suppl (Stockh) 1994; 186: 47.
74. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; 2: CD005028.
75. Nolting S, Hagemeier HH,. Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution. Fortschr Med 1983; 101: 1679-1683.
76. Hillstrom L, Pettersson L, Svensson L,. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp. J Int Med Res 1982; 10: 419-422.
77. Tauber U, Weiss C, Matthes H,. Does salicylic acid increase the percutaneous absorption of diflucortolone-21-valerate? Skin Pharmacol 1993; 6: 276-281.
78. ® versus dipropionate de betamethasone 0.05% + acide salicylique 3% pommade anhydre dans le traitement local de dermatoses corticosensibles chroniques á composante keratosique ou squameuse: etude mulicentrique européenne. Abstract Dermato Hebdo 1992; 159: 1-4.
79. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000; 42: 1008-1011.
80. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39: 590-596.
81. Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001; 40: 468-471.
82. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135: 60-64.
83. Koo JY, Martin D,. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40: 210-212.
84. Buder K, Knuschke P, Wozel G,. Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010; 48: 814-820.
85. Kowalzick L,. Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. Br J Dermatol 2001; 144 (Suppl. 58): 21-25.
86. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-654.
87. Ruzicka T, Lorenz B,. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258.
88. Simonsen L, Hoy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm 2004; 30: 1095-1102.
89. Traulsen J, Hughes-Formella BJ,. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003; 207: 166-172.
90. Traulsen J,. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol 2004; 43: 611-617.
91. van de Kerkhof PC, Wasel N, Kragballe K, et al. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005; 210: 294-299.
92. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-1173.
93. Kragballe K, van de Kerkhof PC,. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 39-44.
94. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393.
95. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
96. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
97. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-135.
98. Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209: 308-313.
99. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
100. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-113.
101. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-176.
102. Kragballe K, Hoffmann V, Tan J, et al. Calcipotriene plus betamethasone dipropionate gel compared to calcipotriene solution in patients with scalp psoriasis [Abstract P2665. J Amer Acad Dermatol 2008; 58: AB131.
103. Tyring S, Bibby A, Foster R,. A 52-week study of a calcipotriol/ betamethasone dipropionate scalp formulation and ointment in the treatment of psoriasis of the scalp and trunk/limbs in Hispanic/Latino and Black/African American patients [Abstract FP1455. 17th European Academy of Dermatology and Venereology, Paris, France, 17-21 September 2008
104. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-328.